US Stock MarketDetailed Quotes
IINN Inspira Technologies Oxy
- 1.140
- -0.070-5.79%
Close Jul 22 16:00 ET
- 1.190
- +0.050+4.39%
Post 16:01 ET
19.85MMarket Cap-1225P/E (TTM)
1.230High1.100Low109.40KVolume1.190Open1.210Pre Close128.28KTurnover1.03%Turnover RatioLossP/E (Static)17.41MShares2.49052wk High3.45P/B12.16MFloat Cap0.76152wk Low--Dividend TTM10.67MShs Float9.590Historical High--Div YieldTTM10.74%Amplitude0.761Historical Low1.172Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Inspira Technologies Oxy Stock Forum
Inspira™ Technologies Announces Business Targets Presentation Following FDA Clearance and Significant Developments
Inspira Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) announced significant milestones, including FDA clearance for its INSPIRA™ ART100 system. The company will present its business targets and distribution agreements in a conference call on June 20, 2024, at 9:00 am Eastern Time. Company President and co-founder Joe Hayon will lead the discus...
INSPIRA™ ART100 Receives FDA 510(k) Clearance
Inspira Technologies OXY announced that its INSPIRA™ ART100 Cardiopulmonary Bypass System has received 510(k) class II clearance from the FDA. The FDA clearance is a significant milestone for the company, suggesting technological and innovative advancements. CEO Dagi Ben Noon and Chairman Professor Benad Goldwasser expressed their appreciation for investors and partners and highlighted the strategic importance ...
NEWS
Inspira™ Announces Start of Production of the INSPIRA™ ART100
Inspira™ Technologies OXY B.H.N. (Nasdaq: IINN, IINNW) has announced the start of production of the INSPIRA ART100 medical device. The device is being contract manufactured by a leading technology company and the first batch will be used in initial sites pending FDA approval.
A recent breakthrough by Inspira™ Technologies and Ennocure MedTech Ltd. has marked a significant milestone. Their latest in vitro study has showcased an unprecedented 100% success rate in preventing the growth of bacteria responsible for bloodstream infections. This development could potentially revolutionize patient care...
No comment yet